New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis

BEERSE, Belgium--(BUSINESS WIRE)--For medical media only -- A series of data presentations released today at the 21st European Academy of Dermatology and Venereology (EADV) congress, in Prague, Czech Republic, demonstrate that STELARA® (ustekinumab) is effective, well tolerated and improved quality of life in patients with moderate to severe plaque psoriasis. Specifically, efficacy results from the 52-week TRANSIT study showed that ustekinumab is highly effective and well-tolerated in patients inadequately responsive to methotrexate,1 and that ustekinumab substantially improved quality of life outcomes in patients transitioned from methotrexate regardless of transition strategy.2 Additionally, results from the PHOENIX 2 study demonstrated that high levels of clinical responses were achieved and maintained through up to five years of ustekinumab treatment.3

Back to news